A Perspective of the Amide Group Containing FDA Approved Anticancer Drugs from 2021–2022 (A Review)
Mohd Asif, Rohan Srivastava, Alisha Fatima, Mazhar Shakeel, Firoz Hassan, Malik Nasibullah
Abstract
Abstract In this review, we describe a collection and assessment of 16 anticancer drugs approved by the U.S. FDA between 2021 to June 2022, which include small and big amide group containing compounds. All the 16 drugs have been approved for the treatment of different types of cancer. The amide group containing approved drugs listed and described in the following order: year of permission, donor, goal, pharmacological category, and significant drug-metabolizing enzyme, technique of administration or elimination mechanism, and pharmacological and toxicological susceptibility. Moreover, the skeleton of the approved drugs was being also analyzed through stereochemistry. The aromatic/aliphatic character of the molecules has been made important in pharmacophores and effective elements such as sulphur, nitrogen, halogens, and active functional groups. The diversity of effective drugs for cancer treatment is needed for the present.